In this issue
Insight
We need to reassess how we measure and treat pain as opioid addiction growsSubscription
Removing official pain measures will not alleviate the rising number of patients addicted to opioid drugs — a better way to determine pain is required.
CPD article
Biosimilars and inflammatory bowel disease: a switch programme using CT-P13Subscription
How to plan and manage switching patients from a biologic to a biosimilar in inflammatory bowel disease, using the University Hospital Southampton NHS Foundation Trust’s experience as an example.
Review
Cardiovascular side effects of cancer treatmentsSubscription
The cardiovascular side effects of cancer treatments remain a challenge in oncologic care.
Research Article
Assessing the impact of a targeted pharmacist-led anticoagulant review clinicSubscription
Local guidance, supported by the 2014 National Institute for Health and Care Excellence (NICE) guideline CG180 for atrial fibrillation (AF), recommends that patients receiving inadequate anticoagulation with a vitamin K antagonist (VKA), including time in therapeutic range (TTR) of <65%, should be reassessed. These patients were identified by the anticoagulation monitoring service (AMS) and highlighted to GPs for review. However, up to 59.3% of patients received ...
Short Communications
Improving the care of people with learning disabilities in pharmacySubscription
There are about 1.2 million people in England with a learning disability. A number of recent studies have ...
Talk about medicines week Subscription
We are writing to share with you our learning and experience on an annual patient and multidisciplinary education event.
NHS England tried hard to manage funding of new hepatitis C drugsSubscription
I read with interest the letter from Charles Gore of The Hepatitis C Trust asking why NHS England is treating people living with hepatitis C as exceptional cases and has capped the access to medicines that can eradicate the infection in most cases.
